CytoDyn Reports Prolonged Survival With Leronlimab in Metastatic Triple-Negative Breast Cancer
I'm PortAI, I can summarize articles.
CytoDyn Inc. will present new clinical data on leronlimab in metastatic triple-negative breast cancer at the San Antonio Breast Cancer Symposium, December 9-12, 2025. The data suggest leronlimab may increase PD-L1 levels, potentially improving immune checkpoint inhibitor efficacy. The presentation by Dr. Milana V. Dolezal from Stanford University will focus on prolonged survival. Materials will be posted on CytoDyn’s website after the presentation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments